Solving Riddles Through Sequencing
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
During the last decades hematologists have excelled at improving and refining the classification, diagnosis, and thus ultimately the therapeutic decision-making process for their patients. This continuous evolution proceeded in parallel to seminal discoveries in basic science such as FISH, PCR and NGS. So far, the current WHO classification serves as reference to diagnostic decision making and is largely based on 5 diagnostic pillars: cytomorphology of peripheral blood and/or bone marrow smears, histology and immunohistochemistry of bone marrow trephine biopsies or lymph nodes, immunophenotyping, chromosome banding analysis supplemented by FISH analysis, molecular genetics including PCR and targeted panel sequencing via NGS. This leads to a swift diagnosis in 90 % of all cases. The leftover 10 % remain a challenge for hematopathologists and clinicians alike and are resolved through interdisciplinary teams in the context of specialized boards. With the advent of high throughput sequencing (mainly WGS and WTS) the possibility of a comprehensive and detailed portrait of the genetic alterations - specifically in challenging cases - has become a realistic alternative to classical methods. In SIRIUS the investigators will prospectively challenge this hypothesis to address the question of how often a better or final diagnosis can be delivered by WGS and/or WTS and if unclear cases can be efficiently resolved.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjent z podejrzeniem choroby hematologicznej (choroby krwi), która pozostaje niewyjaśniona po standardowych badaniach
- •Wiek minimum 18 lat
- •Niespodziewany przebieg choroby lub brak odpowiedzi na leczenie
- •Próbka krwi lub szpiku kostnego zawierająca co najmniej 20% komórek nowotworowych
- •Pisemna zgoda pacjenta na uczestnictwo w badaniu
✗ Disqualifies
- •Próbka niedostarczona w odpowiednich warunkach (uszkodzenie podczas transportu, zły antykoagulant)
- •Próbka zawiera mniej niż 20% komórek nowotworowych
- •Próbka nie spełnia standardów jakości niezbędnych do prawidłowej diagnostyki
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 99 Years
- Last updated (source)
- October 9, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
MLL Munich Leukemia Laboratory
Munich, Germany
Trial contact
Torsten Haferlach, MD
Adam Wahida, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/10/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.